Últimas noticias sobre WANG & LEE Group (NASDAQ:WLGS) Bolsa

WANG & LEE Group

WANG & LEE Group Inc operates as an investment holding company. The firm conducts its primary operations through its indirectly wholly owned subsidiary WANG and LEE CONTRACTING LIMITED (WLHK). WLHK provides contract engineering, installation, and out-fitting of the following products and services: low voltage (220v/phase 1 or 380v/phase 3) electrical systems, mechanical ventilation and air-conditioning systems (MVAC), fire safety systems, and water supply and sewage disposal systems.

WANG & LEE Group Inc

WIIM

Eaton Corporation shares are trading lower after RBC Capital lowered its price target on the stock from $405 to $376.

Cracker Barrel Old Country Store, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRL#NASDAQ">CBRL</a>) shares are <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44163329/cracker-barrel-reports-second-quarter-fiscal-2025-results-and-increases-guidance" rel="noreferrer noopener">trading higher on Thursday.</a>
The company reported second-quarter adjusted earnings per share of $1.38 beating the street view of $1.00. Quarterly sales of $949.44 million (+1.5% year over year), outpaced the analyst consensus estimate of $943.58 million.
Comparable store restaurant sales increased 4.7%, and comparable store retail sales increased 0.2%.
Adjusted EBITDA was $74.6 million, a 19.6% increase compared to the prior year&#8217;s adjusted EBITDA of $62.4 million. Adjusted EBITDA margin expanded to 7.9% from 6.7% in the year-ago period.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/global/25/03/44164241/trump-administration-weighs-sea-inspections-of-iranian-oil-tankers" rel="noreferrer noopener">Trump Administration Weighs Sea Inspections Of Iranian Oil Tankers</a>
&#8220;Despite some recent industry-wide softness, these results, together with the continued improvements in key guest and operational metrics and the initiatives we have planned for our important fourth quarter, make us confident in raising our financial outlook for the remainder of the year,&#8221; Cracker Barrel President and Chief Executive Officer&nbsp;Julie Masino&nbsp;said.
The company&#8217;s quarterly dividend of&nbsp;$0.25&nbsp;per share is payable on&nbsp;May 14, 2025,&nbsp;to shareholders of record as of&nbsp;April 11, 2025.
Outlook: Cracker Barrel revises FY25 total revenue outlook from $3.4 billion &#8211; $3.5 billion to $3.45 billion &#8211; $3.50 billion (estimate: $3.46 billion).
Adjusted EBITDA is expected in the range of&nbsp;$210 million&nbsp;to&nbsp;$220 million&nbsp;versus the previous outlook of&nbsp;$200 million&nbsp;to&nbsp;$215 million.
Price Action: CBRL shares are trading higher by 20.6% to $48.59 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44163875/burlington-beats-earnings-sales-in-q4-stock-jumps" target="_blank" rel="noreferrer noopener">Burlington Stock Jumps As Q4 Earnings Crush Estimates, But CEO Warns Of &#8216;Uncertain&#8217; 2025 Outlook</a></li>
</ul>

Earnings

Equities

News

Guidance

Markets

Movers

General

CBRL

Cracker Barrel Stock Jumps On Q2 Earnings Beat, Raises FY25 Outlook

Trading Ideas

ACON

Aclarion Shares Halted On Circuit Breaker To The Downside, Stock Now Down -81%

On Wednesday,&nbsp;the FDA approved&nbsp;ARS Pharmaceuticals, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRY#NASDAQ">SPRY</a>) neffy&nbsp;1 mg&nbsp;(epinephrine nasal spray) for Type I Allergic Reactions, including anaphylaxis, in children who are aged 4 years and older and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">weigh 15 to &lt; 30 kilograms</a>.
The approval represents the first significant innovation in the delivery of epinephrine for this patient population<a href="https://www.benzinga.com/pressreleases/25/03/g44151949/ars-pharmaceuticals-announces-fda-approval-of-neffy-1-mg-epinephrine-nasal-spray-for-type-i-allerg" target="_blank" rel="noreferrer noopener"> in more than 35 years</a>. 
Approval of neffy 1 mg follows FDA approval for neffy 2 mg for children and adults weighing 30kg and for EURneffy in the EU by the European <a href="https://www.benzinga.com/general/biotech/24/08/40531242/newly-approved-ars-pharmaceuticals-needle-free-neffy-offers-convenience-over-epipen-for-allergic-" target="_blank" rel="noreferrer noopener">Commission in August 2024</a>.
The approval of&nbsp;neffy&nbsp;1 mg&nbsp;is based on data from clinical trials, including pharmacokinetic (PK) and pharmacodynamic (PD) responses&nbsp;in pediatric and adult subjects&nbsp;consistent with those of epinephrine injection products.
Adverse events in pediatric trials were generally mild and transient.
The device has a shelf-life of 24 months at room temperature and tolerance to temperature exposures up to 122°F (50°C) based on testing for up to 3 months. If accidentally frozen, it can be thawed without impacting the product&#8217;s quality and reliability.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41876225/ars-pharmaceuticals-inks-licensing-pact-for-neffy-allergic-reaction-treatment-analyst-sees-further-stock-upside-despite-200-surge-in-2024" rel="noreferrer noopener">ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024</a>
Most commercially insured patients will pay no more than $25 for two single-use neffy devices through a co-pay savings program.
If the product isn&#8217;t covered by insurance, the&nbsp;cash price of $199 for two doses is available through BlinkRx and coupon can be downloaded from GoodRx for use at local retail pharmacies.
For certain uninsured or underinsured U.S. residents meeting eligibility criteria and exhausted all other options, the ARS Pharma Patient Assistance Program will provide&nbsp;neffy&nbsp;at no cost.
William Blair analyst Lachlan Hanbury-Brown writes, &#8220;While the approval was largely expected, we believe it nonetheless represents an important milestone for the company as it advances the launch of neffy 2 mg.&#8221;
The analyst noted that although Neffy 1 mg accounts for only about 15% of the epinephrine market by volume, the company&#8217;s research shows that needle phobia is most common in children.
Many caregivers are also hesitant to use needle-based autoinjectors on their children, which could drive higher adoption of neffy among pediatric patients.
In the U.S., nearly 40% of epinephrine prescriptions are for children. Since its September launch, about two-thirds of Neffy 2 mg prescriptions have been for children, indicating strong early adoption in this group.
Price Action: SPRY stock is down 1.29% at $10.73 during the premarket session at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44149088/disney-cuts-200-jobs-across-abc-and-tv-networks-amid-restructuring" target="_blank" rel="noreferrer noopener">Disney Cuts 200 Jobs Across ABC News And Disney Entertainment Networks: Report</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

SPRY

FDA Approves ARS Pharmaceuticals' Lower Dose Neffy Nasal Spray For Emergency Allergy Treatment

RBC Capital analyst Michael Carroll maintains Lineage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) with a Outperform and lowers the price target from $81 to $74.

Price Target

Analyst Ratings

LINE

RBC Capital Maintains Outperform on Lineage, Lowers Price Target to $74

Loop Capital analyst Gary Mobley upgrades Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) from Hold to Buy and announces $110 price target.

Upgrades

MRVL

Loop Capital Upgrades Marvell Tech to Buy, Announces $110 Price Target

Insider Trades

AIM ImmunoTech Form 4 Filing Shows CEO Thomas K Equels Bought 50,000 Shares At An Average Price Of $0.13/Share

RBC Capital analyst Michael Carroll maintains EPR Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPR#NYSE">EPR</a>) with a Outperform and raises the price target from $50 to $58.

RBC Capital Maintains Outperform on EPR Props, Raises Price Target to $58

Macro Economic Events

Economics

Federal Reserve

Fed's Harker Says It Never Turns Out Well When Central Bank Independence Is Eroded; Worried That Decline In Inflation Pressure Is At Risk

RBC Capital analyst Nik Modi reiterates Brown-Forman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) with a Sector Perform and maintains $44 price target.

Reiteration

BF/B

RBC Capital Reiterates Sector Perform on Brown-Forman, Maintains $44 Price Target

Conduit Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") announces that, on February 11, 2025, the Company presented its plan of compliance to The Nasdaq Stock Market LLC ("Nasdaq") Hearing Panel (the "Panel") and requested an extension of time to achieve compliance with Nasdaq Listing Rules 5450(a)(1), 5450(b)(2&amp;3)(C) and 5450(b)(2)(A), the Minimum Bid Price ("Bid Price"), Market Value of Publicly Held Shares ("MVPHS") and Market Value of Listed Securities ("MVLS") rules, respectively.
On March 5, 2025, the Company received a written notification (the "Notice") from the Panel confirming it has granted the Company such an extension for the Company to regain compliance with the MVPHS and MVLS rules, provided that the Company, (i) on or before March 12, 2025, files an application to transfer to the Nasdaq Capital Market, which it intends to do, and (ii) on or before March 31, 2025, demonstrates compliance with all Nasdaq listing rules, which it also intends to do, and believes it will satisfy.
Additionally, the Company was also notified in the Notice that as of February 26, 2025, it had regained compliance with Nasdaq Listing Rule 5450(a)(1), the Bid Price rule.
Following the transfer to the Nasdaq Capital Market, the Company's current MVPHS will be compliant with the MVPHS continued listing standard of greater than $1.0 million and the Company believes it will be able to demonstrate its compliance with the Equity Standard of Stockholder's Equity greater than $2.5 million prior to the March 31, 2025, deadline to the satisfaction of Nasdaq, although no such assurance can be given.

Conduit Pharmaceuticals Received Written Notification From The Panel Confirming It Has Granted The Co An Extension To Regain Compliance On Or Before March 12, 2025

Piper Sandler analyst Harsh Kumar maintains Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Overweight and lowers the price target from $120 to $95.

Piper Sandler Maintains Overweight on Marvell Tech, Lowers Price Target to $95

Aclarion Announces Expansion Of Nociscan Access In New York And New Jersey With RadNet Affiliates To Meet Growing Demand

RBC Capital analyst Deane Dray maintains Eaton Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) with a Outperform and lowers the price target from $405 to $376.

RBC Capital Maintains Outperform on Eaton Corp, Lowers Price Target to $376

Barclays analyst Raimo Lenschow maintains MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Overweight and lowers the price target from $330 to $280.

Barclays Maintains Overweight on MongoDB, Lowers Price Target to $280

Piper Sandler analyst Brent Bracelin maintains MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Overweight and lowers the price target from $425 to $280.

Piper Sandler Maintains Overweight on MongoDB, Lowers Price Target to $280

In the current market session, AutoZone Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) stock price is at $3544.81, after a 0.31% drop. However, over the past month, the company's stock spiked by 2.25%, and in the past year, by 15.11%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1741272347_0.png" alt="Past Year Chart" />

<h3>AutoZone P/E Compared to Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
AutoZone has a lower P/E than the aggregate P/E of 25.24 of the Specialty Retail industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1741272347_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Price Over Earnings Overview: AutoZone

Shaquille O'Neal is known for a lot more than just basketball. The NBA Hall of Famer has built an empire that spans fast food franchises, real estate, tech investments, and even his own cookbook. With a <a href="https://www.benzinga.com/personal-finance/24/11/41869301/shaqs-got-a-500-million-fortune-but-his-kids-arent-getting-a-dime-without-earning-it-you-need-3-degrees-to-touch-daddys-cheese">net worth exceeding $500 million</a>, he's one of the wealthiest athletes-turned-entrepreneurs in America. But despite his success, Shaq keeps it simple when it comes to food.
<h2 class="wp-block-heading">Keeping It Real in the Kitchen</h2>
"I don't like rich people food," he <a href="https://www.youtube.com/watch?v=uLjK50xc9XI">admitted</a> on &#8220;The Late Show with Stephen Colbert&#8221; in 2022 while promoting his cookbook "Shaq's Family Style: Championship Recipes for Feeding Family and Friends." When asked what he meant, he joked, "I don't like hors d&#8217;oeuvres. We regular people, we like chicken wings. I want chicken wings, pizza, and chips. Keep it simple.&#8221;
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
Shaq's cookbook, which he dedicated to his mother, features easy, hearty meals inspired by his family. "During the pandemic, when there was just nothing to do, I finally [told my chefs], ‘Teach me how to cook.' Before you knew it, I was cooking 10 to 15 dishes," he said. Now, he's passing those recipes along to fans who, like him, prefer comfort food over fancy dining.
<h2 class="wp-block-heading">Shaq's Business Mindset</h2>
While Shaq keeps things casual in the kitchen, he takes a strategic approach to business. Dubbed by some as &#8220;The King of Franchises,&#8221; he has <a href="https://www.benzinga.com/startups/24/10/41273376/im-not-in-this-to-become-a-trillionaire-said-shaq-on-starting-his-big-chicken-restaurants-its-about">owned and invested</a> in multiple restaurant chains, including Papa John's, Krispy Kreme, Five Guys, and Auntie Anne's. But not every venture has worked out.
In 2021, he revealed on the Earn Your Leisure podcast that he <a href="https://www.benzinga.com/startups/24/12/42468734/nba-legend-shaq-owned-17-auntie-annes-franchises-but-sold-them-after-realizing-black-people-dont-like-pretzels-that-much">sold his 17 Auntie Anne's</a> locations because "Black people don't like pretzels that much." When the hosts mentioned cinnamon pretzels, Shaq dismissed it: "Nobody eats no cinnamon pretzels."
Trending: <a href="https://www.benzinga.com/money/qnetic-2">This 12,000 RPM Spinning Battery With Over $100 Million In LOIs Could Be The Missing Link For Green Energy — Here&#8217;s Why Early Investors Are Flocking To Invest Before Funding Closes</a>
This isn't the first time he's made a business decision based on cultural insights. He once <a href="https://www.benzinga.com/startups/24/10/41144354/shaq-missed-a-deal-of-a-lifetime-with-starbucks-says-because-growing-up-hes-never-seen-a-black-perso">turned down an opportunity</a> with Starbucks, telling CEO Howard Schultz, "Black people don't drink coffee, sir." He later admitted it was one of his biggest financial mistakes. "It was a mistake, but I learned from it," he said.
<h2 class="wp-block-heading">A Franchise Mogul With A Personal Touch</h2>
Though Auntie Anne's didn't work out, Shaq found success with Papa John's, where he owns nine locations and serves on the board of directors. His involvement came after founder John Schnatter stepped down following controversy. "For me, it was a great thing to do. The guy just messed up, but he had to pay for that. Now I'm just gonna make sure it's right," Shaq said. He also secured an $11 million endorsement deal with the company.
His success in business comes from knowing when to pivot. "You gotta switch it up," he often says, whether it's in food, business, or life. And while he might not like ‘rich people food', he certainly knows how to build wealth.
Read Next:
<ul>
<li>It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

Shaquille O'Neal, One Of The Wealthiest Americans, A Cookbook Author And 'The King Of Franchises,' Admits 'I Don't Like Rich People Food'

ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) has outperformed the market over the past 5 years by 8.55% on an annualized basis producing an average annual return of 23.36%. Currently, ServiceNow has a market capitalization of $184.50 billion. 
Buying $100 In NOW: If an investor had bought $100 of NOW stock 5 years ago, it would be worth $305.90 today based on a price of $893.50 for NOW at the time of writing.
<h3>ServiceNow's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741272308_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Piper Sandler analyst Matt O'Brien maintains Sight Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGHT#NASDAQ">SGHT</a>) with a Neutral and lowers the price target from $5.5 to $3.5.

SGHT

Piper Sandler Maintains Neutral on Sight Sciences, Lowers Price Target to $3.5

Press Releases

WANG & LEE GROUP, INC. Announces Fiscal Year 2023 Financial Results

Wang & Lee Group Enters Strategic ESG Partnership with Jinshan Hi-Tech Group for Innovative Waste Treatment Solutions

Wang & Lee Group, Inc. Partners with City University of Hong Kong for Groundbreaking Kinetic Energy Project

Wang & Lee Group, Inc. Collaborates with City University of Hong Kong to Develop Advanced Eco-Friendly Lithium-Ion Battery Technology for Electric Bicycles, automotive and robotics

Comments

WANG & LEE Group

Noticias

Últimas noticias sobre WANG & LEE Group (NASDAQ:WLGS) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL